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Background: ABO-incompatible live donor liver transplant (ABOi-LDLT) is being widely done to bridge the gap
of demand and supply of organs. Different desensitization regimes are being used to reduce titer of blood group
antibodies for successful transplant and accommodation of graft. The authors used cascade plasmapheresis (CP)
to bring down titer of naturally occurring blood group antibody to 16 or lower.
Material and methods: Four recipients of ABOi-LDLT were of blood groups O, O, B, and B while donors were
of blood groups B, A, AB, and AB, respectively. Desensitization protocol included immunosuppressive drugs and
plasmapheresis. CP consisted of separating patient’s plasma as the first step and passing it through pore size based
filter column as the second step. The first step was performed using disposable kit (PL1, Fresenius Kabi, Germany)
with minor modification on apheresis equipment COM.TEC (Fresenius Kabi, Germany). Pore size based filter column
used was 2A column (Evaflux, Kawasumi Laboratories, Japan). Blood group antibody titer (immunoglobulin G (IgG))
was done by column agglutination technology (Ortho-Clinical Diagnostics).
Results: Cases 1, 2, 3, and 4 with pre-CP titer of 1,024, 512, 32, and 64 required four, three, one, and one CP
procedures, respectively. No signs of antibody-mediated rejection were exhibited on histopathological evaluation
by any of the patients. Successful organ engraftment occurred as documented by post-operative liver function tests
and liver biopsy.
Conclusion: Cascade plasmapheresis offers a cost-effective and efficient way to decrease blood group antibody
titer and helps in successful transplant.
Keywords: Cascade plasmapheresis, Plasmapheresis, Transplant, Titer, ABO-incompatible transplant, ABO-compatible
transplant, ABO-incompatible live related donor liver transplants (ABOi-LDLT)Background
A large number of liver transplants are being performed
in India, and majority is live donor liver transplant (LDLT)
[1]. In India, the organ transplants are governed by Organ
Donation Act [2], which allows only first-degree relatives
or spouse to be donor(s) for the patient. Sometimes this
willing donor is not suitable on the grounds of ABO blood
group incompatibility. However, in recent times, people
have found their way around this ‘suitability issue’ by* Correspondence: aseemtwr@yahoo.co.in
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successfully using various desensitization protocols [3,4].
Desensitizing protocols play an important role in
successful outcome of these transplants by decreasing
the chances of acute antibody-mediated organ rejection
[4]. These protocols include immunosuppressive drugs
and plasmapheresis. Immunosuppressive drugs inhibit
the formation of new antibodies, and plasmapheresis
lowers the titer of existing blood group antibodies.
There is a report from India reiterating pivotal role of
plasmapheresis in desensitization protocols leading to
successful solid organ transplant and adequate patient
follow-up after the transplant, as well [5]. However, thistd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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plasma, and volume replacement was done with normal
saline and donor fresh frozen plasma (FFP) units. We
would like to present a case series of four consecutive
ABOi-LDLT patients where we used cascade plasmapher-
esis (CP) successfully as a part of preconditioning regime
to reduce the titer of naturally occurring antibody in ABO
incompatible LDLT.
Materials and methods
Patient and donor selection
Four patients with end-stage liver disease (ESLD) who
did not have ABO-compatible donor in the family were
enrolled for ABOi transplant program. They were explained
about the process of ABOi-LDLT including the plasma-
pheresis protocol (CP) with its potential benefit in reducing
antibody titer and possible adverse effects like citrate effect
and changes in blood pressure, etc. Informed consent was
obtained for CP from the patients. All the prospective
donors underwent extensive medical and psychological
assessment. The donors who qualified these assessments
were briefed about the surgery, its duration, risks, length
of stay in the hospital, etc. The donors then provided
written consents for organ donation. The demographic
profile, primary diagnosis, comorbid conditions, model
for end-stage liver disease (MELD) score of these four
patients, and demographic profile of their donors are
given in Table 1.
Desensitization protocol
Desensitization protocol included immunosuppressant
drugs and cascade plasmapheresis.
Immunosuppressant drug regime
The drug regime was started with anti-CD20 drug
(rituximab) which was administered as a single dose of
100 mg, 19 days prior to planned date of surgery to inhibit
formation of new antibodies. Thereafter, plasmapheresis
was initiated to remove the existing blood group anti-
bodies till the titer of 16 or lower was achieved. The other
three immunosuppressive drugs (mycophenolate mofetil,
tacrolimus, and glucocorticoids) were initiated prior toTable 1 Profile of the patients and donors
Patient
Case number Age and gender Diagnosis Comorbid conditions
(indication for transpla
Case 1 33/F HCV-related chronic
liver disease (CLD)
Jaundice, ascites, PH
Case 2 42/M Crypotogenic CLD Jaundice, ascites, HRS
Case 3 56/M HCV-related CLD SBP, HE, Ascites
Case 4 59/F HCV-related CLD Cholecystitis, PH , HCC
PH portal hypertension, HRS hepatorenal syndrome, SBP subacute bacterial peritonithe surgery as per the standard hospital protocol. Oral
mycophenolate mofetil (MMF) 500 mg/twice a day was
started 7 days prior to LDLT. Tacrolimus was initiated
on the day of LDLT, and tacrolimus trough level was
maintained between 10–15 ng/ml in the first 2 weeks,
7–10 ng/ml between 2–12 weeks, and 5–7 ng/ml until
6 months. Prednisolone was administered on the day of
surgery at a dose of 2 mg/kg for 1 week, then at 1 mg/
kg for 2 weeks, then gradually tapered to 0.5 mg/kg by
fourth week, and stopped 3 months after surgery. MMF
and tacrolimus were continued for life. These three
drugs were also used in ABO-compatible (ABOc) liver
transplants.Cascade plasmapheresis
CP was initiated after an average of 19 days (range 11–
24 days) after rituximab administration. CP consisted of
separating patient’s plasma as the first step and passing it
through a pore size based filter column as the second step.
The first step was performed using plastic disposable
kit (PL1, Fresenius Kabi, Germany) on the apheresis
equipment COM.TEC (Fresenius Kabi, Germany). The
pore size based filter column used was 2A column (Evaflux,
Kawasumi Laboratories, Japan) [6]. This column comes
with tubing which is compatible and was used in con-
junction with PL1 kit. The attachments were made
under sterile conditions (laminar airflow) in a manner
that the separated plasma would be the ‘inflow’ to the
filter and the filtered plasma would be ‘reinfusion’ in
the PL1 kit and thus, completing the vein to vein
circuit. Though the disposable kit prescribed by the
manufacturer for such procedures is P1R, the authors
adapted routine kit used for plasma exchange PL1 for
CP procedures. In PL1 kit used for conventional plas-
mapheresis, the separated plasma is replaced via the re-
placement of fluid pump (white) generally at the ratio
of 1:1. The loop of the kit which passes through the
replacement fluid pump was kept outside the pump in
the modified circuit (Figure 1). This minor modification
was done since there was no need of 1:1 replacement.
The replacement, if any, was done with 5% albumin
through a separate intravenous line.Donor Titer
nt
MELD score Blood group Relationship
with patient
Blood group Baseline titer
19 O positive Sibling B positive 2,048
19 O positive Wife A positive 1,024
18 B negative Daughter AB positive 64
19 B positive Daughter AB positive 64
tis, HE hepatic encephalopathy, HCC hepatocellular carcinoma.
Figure 1 Conventional and modified PL1 circuits.
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The pore size based column was a semi-selective column
and manufactured in different pore sizes (2A, 3A, 4A, 5A).
The 2A column performs well with separation of globulins
and albumin. The sieving coefficient of the column for IgM
is 0.0, immunoglobulin G (IgG) is 0.2, and albumin is 0.62.
The sieving coefficient is defined as the ratio of a solute
in the filtrate to the simultaneous concentration of the
same solute in the plasma. In other words, sieving coef-
ficient is the ratio of solute returned to the patient. The
manufacturer markets the 2A column for various applica-
tions including nephrologic (rapidly progressive glomerulo-
nephritis, Goodpasture’s syndrome, ABOi renal transplant),
dermatologic (pemphigus vulgaris, bullous pemphigoid),
systemic lupus erythematosus, neurologic (myasthenia
gravis, Guillain-Barre syndrome, chronic inflammatory
demyelinating polyradiculoneuropathy), etc. With the
understanding of the principle, the authors used 2A
column for decreasing the antibody titers in ABOi-LT.
Titer
The blood group antibody titer was done by column
agglutination technology (Ortho-Clinical Diagnostics).
The cassettes used were anti-IgG, anti-C3d, and polyspe-
cific (Ortho BioVue System, Ortho-Clinical Diagnostics,High Wycombe, UK), and the technique was low ionic
salt solution-indirect antiglobulin test (LISS-IAT). The
procedure was the same as published previously [5],
and only IgG was considered to decide upon patient
management. The titer was done before and after each CP
procedure before surgery, daily for 7 days after surgery,
and at least twice weekly till 6 weeks post-surgery.
Ethical clearance
The protocols used for desensitization were ‘standard of
care’. The study was purely an observational one, and
therefore, no ethical approval was needed.
Result
The desired titer of 16 or lower was achieved in one to
four CP procedures. The cases 1, 2, 3, and 4 with the
pre-CP titer of 2,048, 1,024, 32, and 64 required four,
three, one, and one CP procedures, respectively. Figure 2
shows titer in the four patients, respectively. Titer of the
three patients (except case 2) remained low (below 16)
throughout the post-operative period. In case 2, the
titer went up from 16 to 128 post-LDLT along with
increment in liver enzymes necessitating intravenous
immunoglobulins (IVIG) and three consecutive CP on





















Baseline Pre CP P1 P2 P3 P4 day of
Surgery
POD1 DOD
Case 1 Case 2 Case 3 Case 4
Figure 2 Changes in ABO antibody titers (Baselines titers = titer was done prior to rituximab administration; Pre-CP = Pre-cascade
plasmapheresis, titer was done before the first CP; P = Procedure; POD = Post-operative day; DOD = day of discharge).
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No histopathological evidence of antibody-mediated
rejection was exhibited by any of the four patients in
the biopsy performed at 1 month (protocol biopsy)
post-LDLT. Successful organ engraftment occurred as
documented by post-operative liver function tests, ultra-
sonography, and liver biopsy. Two out of four patients
(case no. 3 and 4) had sinus ventricular tachycardia,
two and 17 days post-LDLT, respectively, which was
managed by intravenous diltiazem. Antibiotics administered
prophylactically to all four patients were pipracillin-
tazobactum and teicoplanin. Case no. 3 required additional
antibiotics (linezolid, polymixin E, and meropenem) on
post-operation day 3 based on culture and sensitivity of
blood and endotracheal tube secretions. All the four
patients were discharged after an average of 21 days
(range 20–23 days) with dietary and medical advice.
Follow-up regime after discharge was once a week
until 3 months, once a fortnight till sixth month, once a
month till 2.5 years, and once every 2 months till life.
Case 1 was readmitted on post-operation day 56 with
acute pancreatitis. She succumbed despite 5 days of
active medical management. All other three patients
continue to do well with mean follow-up of 9 months.Discussion
Rituximab was given to all four patients to inhibit the
formation of new antibodies and thus, decrease the titer of
naturally occurring blood group antibodies. Plasmapheresis
was subsequent to antibody titer decrease obtained by
rituximab alone as evidenced by antibody titer monitoring.
However, either there was no decrease in titers or at best
decrease by one dilution. Plasmapheresis sessions achieved
the desired levels of 16 or less thereafter. Plasmapheresis,therefore, remains an integral part of any desensitization
regime.
Plasmapheresis can be conventional, cascade, or adsorp-
tion. While the conventional plasmapheresis is completely
nonspecific with removal of entire plasma and its substitu-
tion with replacement fluid like FFP, albumin, normal saline
alone, or more commonly in combination; cascade plasma-
pheresis is semi-selective with removal of high molecular
weight substances mainly immunoglobulins; and some
amount of albumin and adsorption column plasmapheresis
is the most specific with removal of only ABO-specific
immunoglobulins.
In India, solid organ transplant with conventional
plasmapheresis is already reported [5]. Our series of ABOi
solid organ transplants with CP with slight modification is
probably one of the first such reports. The advantages of
cascade plasmapheresis are that largely immunoglobulins
are removed (100% IgM, 80% IgG) and most of the albu-
min and other plasma proteins (62%) are returned to the
recipient. Though small amount of albumin is lost, it is
much smaller as compared to conventional plasmapher-
esis. This also means that there is a very little need for
replacement fluids. The mean amount of replacement fluid
(5% albumin) required in our four patients was 500 ml
(range = 250–700 ml). The lower volume of replacement
fluid required in this series is in agreement with other
published reports [7]. The procedure resulted in very little
hemodynamic changes as exhibited by stable vitals of
the patients monitored during the procedures. Further,
as against the number of conventional plasmapheresis
procedures required to achieve the desired titer, the
number of CP procedures in our series was substantially
fewer as shown in Table 2.
This translated into multiple advantages for the patient.
The patients could undergo early transplants which
Table 2 Comparison between numbers of plasmapheresis procedure required as per guidelines and number of
procedures in the present series and their costing




procedures in US dollars






Case 1 (2,048) 10–12 6,417 4 3,333 3,084
Case 2 (1,024) 10–12 6,417 3 2,500 3,917
Case 3 (32) 3 1,750 1 834 916
Case 4 (64) 4–5 2,625 1 834 1,791
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of infection due to fewer interventional procedure, and
better patient compliance. Though the disposable kit pre-
scribed by the manufacturer for such procedures is P1R,
the authors adapted routine kit used for plasma exchange
PL1 for CP procedures. This was easily available since PL1
is used very often (for plasma exchange procedures), and
it also meant that the authors did not have to maintain
two separate inventories of P1R and PL1. Though individ-
ual CP procedure was more expensive as compared to
conventional procedure ($834 vs. $584), there was cost
saving since overall number of procedures in all four cases
were substantially lower as compared to the possible num-
ber of conventional procedures (Table 2).
Most centers would possibly not consider a patient
with baseline titer higher than 512 for ABOi transplant.
The authors had to take two patients for ABOi trans-
plants with titer higher than 512 (2,048 and 1,024) since
there were no suitable ABOc donors, and patients’ con-
dition were deteriorating. Post-operatively titers were
monitored daily, and in three patients, they remained
low (<16). However, in one patient (case 2), the titers
rebounded 2 days after surgery with increment in liver
enzymes. This necessitated IVIG and three CP procedure
on alternate days for 6 days before the patient stabilized16








4 4 4 4 4 4 4
Case 1 Case 2
Figure 3 ABO antibody titers in post-surgical period.and the liver enzymes came down to normal values.
Though the titer in case 2 continued to remain high
(Figure 3), the patient did well as per clinical and lab
parameters.
Immediate post-operative follow-up of patients revealed
ventricular tachycardia in two out of the four patients,
which could be managed easily by antiarrhythmic agent.
One patient had to be put on higher antibiotics based on
culture reports to which the patient responded well. One
patient (case 1) was readmitted because of acute pancrea-
titis and died after successful discharge. Larger series of
patients would establish long-term safety of such patients.
Conclusion
ABO blood group hurdle has now been crossed, and
ABO-incompatible solid organ transplants are being
successfully performed in India and other countries.
ABO-incompatible liver transplant can and should be
an option for seriously ill patients, who are awaiting
transplantation and should be offered to all patients in
cases of immediate need of allograft and are without any
blood group compatible organ donor. Cascade plasma-
pheresis using modified PL1 offers a cost-effective and
efficient way to decrease the blood group antibody titer
and helps in successful transplant.8 8 8 8 8 8 8
64
128 128 128 128 128
64 64
32
4 4 4 4 4 4 44 4
Case 3 Case 4
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